Semaglutide 2.4 mg in French people living with Class 3 obesity and comorbidities: Baseline characteristics and real-world safety data.
Disse E, Aron-Wisnewsky J, Jacobi D, Clément K, Laville M, Gauthier C, Pattou F, Molleville J, Akerib M, Jubin L, Gatta-Cherifi B, Gaborit B, Montastier E, Stenard F, Carette C, Achamrah N, Avignon A, Czernichow S; SEMAFEAP Study Group.
Disse E, et al. Among authors: achamrah n.
Diabetes Metab. 2025 May;51(3):101625. doi: 10.1016/j.diabet.2025.101625. Epub 2025 Feb 17.
Diabetes Metab. 2025.
PMID: 39971183